XTL Biopharmaceuticals Ltd. (XTLB)
USD 1.13
(-3.02%)
USD 1.13
(-3.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -764 Thousand USD | 99.8% |
| 2022 | -879 Thousand USD | 84.54% |
| 2021 | -1.03 Million USD | -130.05% |
| 2020 | -947 Thousand USD | -304.85% |
| 2019 | - USD | 94.03% |
| 2018 | -792 Thousand USD | -168.5% |
| 2017 | -1.24 Million USD | -94.08% |
| 2016 | -2.56 Million USD | -129.26% |
| 2015 | -2 Million USD | 79.53% |
| 2014 | -1.96 Million USD | -866.84% |
| 2013 | -190 Thousand USD | 94.99% |
| 2012 | -2.17 Million USD | -257.1% |
| 2011 | -1.11 Million USD | 12.29% |
| 2010 | -1.21 Million USD | -146.9% |
| 2009 | 2.57 Million USD | 127.98% |
| 2008 | -18.4 Million USD | 63.86% |
| 2007 | -25.03 Million USD | -60.85% |
| 2006 | -15.4 Million USD | -51.12% |
| 2005 | -12.37 Million USD | 36.12% |
| 2004 | -16.45 Million USD | -207.17% |
| 2003 | 15.35 Million USD | 186.71% |
| 2002 | -17.71 Million USD | -17.11% |
| 2001 | -15.12 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -175 Thousand USD | 342.8% |
| 2023 FY | - USD | 99.8% |
| 2023 Q4 | 824 Thousand USD | 680.28% |
| 2023 Q1 | -239 Thousand USD | -173.54% |
| 2023 Q2 | -154 Thousand USD | 35.56% |
| 2023 Q3 | -142 Thousand USD | 7.79% |
| 2022 Q2 | -197 Thousand USD | 80.5% |
| 2022 Q4 | 325 Thousand USD | 220.82% |
| 2022 Q3 | -269 Thousand USD | -36.55% |
| 2022 FY | - USD | 84.54% |
| 2022 Q1 | -1.01 Million USD | 62.0% |
| 2021 Q2 | -530 Thousand USD | 29.99% |
| 2021 Q3 | 461 Thousand USD | 186.98% |
| 2021 Q4 | -2.65 Million USD | -676.57% |
| 2021 FY | - USD | -130.05% |
| 2021 Q1 | -757 Thousand USD | -7.07% |
| 2020 Q1 | -534 Thousand USD | -184.36% |
| 2020 FY | - USD | -304.85% |
| 2020 Q2 | -449 Thousand USD | 15.92% |
| 2020 Q4 | -707 Thousand USD | -553.21% |
| 2020 Q3 | 156 Thousand USD | 134.74% |
| 2019 Q4 | 633 Thousand USD | -27.99% |
| 2019 Q2 | -1.6 Million USD | -828.9% |
| 2019 Q1 | -173 Thousand USD | 93.74% |
| 2019 Q3 | 879 Thousand USD | 154.7% |
| 2019 FY | - USD | 94.03% |
| 2018 Q2 | 56 Thousand USD | -93.64% |
| 2018 FY | - USD | -168.5% |
| 2018 Q4 | -2.76 Million USD | -367.64% |
| 2018 Q3 | 1.03 Million USD | 1742.86% |
| 2018 Q1 | 881 Thousand USD | 207.44% |
| 2017 Q2 | -436 Thousand USD | -40.65% |
| 2017 Q3 | 320 Thousand USD | 173.39% |
| 2017 FY | - USD | -94.08% |
| 2017 Q4 | -820 Thousand USD | -356.25% |
| 2017 Q1 | -310 Thousand USD | -166.1% |
| 2016 FY | - USD | -129.26% |
| 2016 Q1 | -575 Thousand USD | 25.42% |
| 2016 Q4 | 469 Thousand USD | 264.56% |
| 2016 Q3 | -285 Thousand USD | 38.71% |
| 2016 Q2 | -465 Thousand USD | 19.13% |
| 2015 Q2 | -479 Thousand USD | -29.11% |
| 2015 Q3 | -385 Thousand USD | 19.62% |
| 2015 Q1 | -371 Thousand USD | -445.59% |
| 2015 FY | - USD | 79.53% |
| 2015 Q4 | -771 Thousand USD | -100.26% |
| 2014 Q4 | -68 Thousand USD | 85.86% |
| 2014 Q1 | -731 Thousand USD | -175.85% |
| 2014 Q2 | -558 Thousand USD | 23.67% |
| 2014 FY | - USD | -866.84% |
| 2014 Q3 | -481 Thousand USD | 13.8% |
| 2013 Q2 | -1.16 Million USD | -14.6% |
| 2013 Q1 | -1.01 Million USD | -206.85% |
| 2013 FY | - USD | 94.99% |
| 2013 Q4 | -265 Thousand USD | -150.0% |
| 2013 Q3 | 530 Thousand USD | 145.61% |
| 2012 Q3 | -1.56 Million USD | -185.22% |
| 2012 Q4 | 949 Thousand USD | 160.72% |
| 2012 Q1 | -400 Thousand USD | -65.98% |
| 2012 FY | - USD | -257.1% |
| 2012 Q2 | -548 Thousand USD | -37.0% |
| 2011 Q4 | -241 Thousand USD | 15.73% |
| 2011 FY | - USD | 12.29% |
| 2011 Q3 | -286 Thousand USD | -5.93% |
| 2011 Q2 | -270 Thousand USD | 12.62% |
| 2011 Q1 | -309 Thousand USD | -2.32% |
| 2010 Q3 | -286 Thousand USD | 8.92% |
| 2010 Q2 | -314 Thousand USD | 5.42% |
| 2010 FY | - USD | -146.9% |
| 2010 Q1 | -332 Thousand USD | -7.79% |
| 2010 Q4 | -302 Thousand USD | -5.59% |
| 2009 Q2 | -1.2 Million USD | -172.7% |
| 2009 FY | - USD | 127.98% |
| 2009 Q3 | 17 Thousand USD | 101.41% |
| 2009 Q1 | 1.66 Million USD | 136.22% |
| 2009 Q4 | -308 Thousand USD | -1911.76% |
| 2008 Q1 | 1.97 Million USD | 107.39% |
| 2008 Q3 | -1.2 Million USD | 66.94% |
| 2008 FY | - USD | 63.86% |
| 2008 Q4 | 704 Thousand USD | 158.67% |
| 2008 Q2 | -3.63 Million USD | -284.26% |
| 2007 Q4 | -26.64 Million USD | -11888.5% |
| 2007 Q1 | 114 Thousand USD | 100.7% |
| 2007 Q2 | -7.6 Million USD | -6772.81% |
| 2007 FY | - USD | -60.85% |
| 2007 Q3 | 226 Thousand USD | 102.97% |
| 2006 Q3 | 114 Thousand USD | 103.04% |
| 2006 Q1 | 114 Thousand USD | 100.74% |
| 2006 Q4 | -16.38 Million USD | -14474.56% |
| 2006 FY | - USD | -51.12% |
| 2006 Q2 | -3.75 Million USD | -3392.98% |
| 2005 Q2 | -2.54 Million USD | -294.79% |
| 2005 Q1 | 1.3 Million USD | 106.73% |
| 2005 Q4 | -15.5 Million USD | -5354.24% |
| 2005 FY | - USD | 36.12% |
| 2005 Q3 | 295 Thousand USD | 111.61% |
| 2004 Q2 | -5.05 Million USD | -684.95% |
| 2004 Q4 | -19.36 Million USD | -2341.67% |
| 2004 Q3 | 864 Thousand USD | 117.1% |
| 2004 FY | - USD | -207.17% |
| 2004 Q1 | 864 Thousand USD | 0.0% |
| 2003 FY | - USD | 186.71% |
| 2002 FY | - USD | -17.11% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -112.53 Million USD | 99.321% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 96.163% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 97.528% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 98.37% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 99.52% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 99.374% |
| Agenus Inc. | -145.92 Million USD | 99.476% |
| Fortress Biotech, Inc. | -133.64 Million USD | 99.428% |
| GlycoMimetics, Inc. | -39.12 Million USD | 98.047% |
| Novavax, Inc. | -487.39 Million USD | 99.843% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 99.498% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -162.543% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 99.179% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -138.006% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 88.876% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 99.704% |
| AlloVir, Inc. | -190.14 Million USD | 99.598% |
| Aptorum Group Limited | -9.59 Million USD | 92.041% |
| Ardelyx, Inc. | -55.35 Million USD | 98.62% |
| Bicycle Therapeutics plc | -183.4 Million USD | 99.583% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 99.538% |
| Chimerix, Inc. | -92.97 Million USD | 99.178% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 98.281% |
| CRISPR Therapeutics AG | -202.7 Million USD | 99.623% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 96.687% |
| Precision BioSciences, Inc. | -32.04 Million USD | 97.616% |
| Dyadic International, Inc. | -8.22 Million USD | 90.717% |
| Elevation Oncology, Inc. | -41.46 Million USD | 98.158% |
| Fortress Biotech, Inc. | -133.64 Million USD | 99.428% |
| GT Biopharma, Inc. | 5.97 Million USD | 112.778% |
| Alkermes plc | 495.04 Million USD | 100.154% |
| Immix Biopharma, Inc. | -16.13 Million USD | 95.265% |
| Innoviva, Inc. | 248.96 Million USD | 100.307% |
| IO Biotech, Inc. | -91.22 Million USD | 99.163% |
| Jaguar Health, Inc. | -33.13 Million USD | 97.694% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 100.751% |
| ContextLogic Inc. | -324 Million USD | 99.764% |
| AbCellera Biologics Inc. | -192.15 Million USD | 99.602% |
| Lantern Pharma Inc. | -15.78 Million USD | 95.16% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 90.9% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 99.565% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 99.799% |
| MEI Pharma, Inc. | 26.38 Million USD | 102.896% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 98.979% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 96.831% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 99.391% |
| NextCure, Inc. | -59.03 Million USD | 98.706% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 99.012% |
| ChromaDex Corporation | -3.89 Million USD | 80.38% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 99.414% |
| Incyte Corporation | 919.42 Million USD | 100.083% |
| Opthea Limited | -200.01 Million USD | 99.618% |
| MiMedx Group, Inc. | 40.51 Million USD | 101.886% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 98.668% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 98.831% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 72.234% |
| Vaxcyte, Inc. | -464.88 Million USD | 99.836% |
| PDS Biotechnology Corporation | -40.08 Million USD | 98.094% |
| Pharming Group N.V. | 9.87 Million USD | 107.735% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 96.644% |
| Onconetix, Inc. | -36.7 Million USD | 97.919% |
| Acelyrin, Inc. | -381.52 Million USD | 99.8% |
| PureTech Health plc | -11.62 Million USD | 93.429% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 99.027% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 99.673% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 95.749% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 96.831% |
| ESSA Pharma Inc. | -26.45 Million USD | 97.112% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 95.501% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 92.335% |
| Seer, Inc. | -97.88 Million USD | 99.219% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 99.126% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 244.423% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 97.362% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -5829.426% |
| Summit Therapeutics Inc. | 1 Million USD | 176.324% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 97.712% |
| Senti Biosciences, Inc. | -61.33 Million USD | 98.754% |
| ImmuCell Corporation | -2.5 Million USD | 69.49% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 99.514% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 98.924% |
| Precigen, Inc. | -89.22 Million USD | 99.144% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 98.654% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 134.183% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 99.32% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 96.781% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 87.509% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.858% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 98.772% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 97.646% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 97.389% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 96.21% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 98.7% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 99.556% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 88.902% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 99.63% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 100.88% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 98.508% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 92.273% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 99.677% |
| Aptose Biosciences Inc. | -52.26 Million USD | 98.538% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 99.291% |
| Soligenix, Inc. | -7.85 Million USD | 90.271% |
| Century Therapeutics, Inc. | -121.2 Million USD | 99.37% |
| Kura Oncology, Inc. | -164.95 Million USD | 99.537% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 99.046% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 92.425% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 20.229% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 82.27% |
| Autolus Therapeutics plc | -156.77 Million USD | 99.513% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 99.098% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 98.893% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 96.167% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 99.596% |
| GRI Bio, Inc. | -10.89 Million USD | 92.99% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 83.081% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 99.376% |
| IGM Biosciences, Inc. | -253.35 Million USD | 99.698% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 99.264% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 97.996% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 95.017% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 95.147% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 98.656% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 99.287% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 99.713% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 99.606% |
| Verastem, Inc. | -83.16 Million USD | 99.081% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 98.489% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 99.517% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 99.33% |
| Histogen Inc. | -10.5 Million USD | 92.726% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 94.65% |
| Surrozen, Inc. | -41.13 Million USD | 98.143% |
| Organovo Holdings, Inc. | -14.8 Million USD | 94.84% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 23922.887% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 98.699% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 98.511% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 96.453% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 90.837% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 99.54% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 98.449% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 96.839% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 94.925% |
| Apollomics, Inc. | -171.74 Million USD | 99.555% |
| Amarin Corporation plc | -50.9 Million USD | 98.499% |
| Mesoblast Limited | -61.33 Million USD | 98.754% |
| Turnstone Biologics Corp. | -56.23 Million USD | 98.641% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 99.466% |
| Synaptogenix, Inc. | -8.3 Million USD | 90.803% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 95.019% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 98.788% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 84.055% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 278.072% |
| Exelixis, Inc. | 196.6 Million USD | 100.389% |
| Better Therapeutics, Inc. | -38.26 Million USD | 98.003% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 99.46% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 99.846% |
| NLS Pharmaceutics AG | -11.79 Million USD | 93.523% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 409.041% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 97.411% |
| Gritstone bio, Inc. | -126.86 Million USD | 99.398% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 98.824% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 80.9% |
| Avid Bioservices, Inc. | -11.48 Million USD | 93.346% |
| Insmed Incorporated | -654.73 Million USD | 99.883% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 66.04% |
| MediWound Ltd. | -4.89 Million USD | 84.386% |
| OmniAb, Inc. | -49.73 Million USD | 98.464% |
| Alector, Inc. | -142.89 Million USD | 99.465% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 99.106% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 98.535% |
| Zai Lab Limited | -366.57 Million USD | 99.792% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 99.737% |
| Aura Biosciences, Inc. | -83.69 Million USD | 99.087% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 99.661% |
| Immunic, Inc. | -99.11 Million USD | 99.229% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 99.42% |
| Veracyte, Inc. | -49.4 Million USD | 98.454% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 89.184% |
| FibroGen, Inc. | -261.4 Million USD | 99.708% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 93.142% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 89.088% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 95.918% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 100.053% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 96.995% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 101.915% |
| TG Therapeutics, Inc. | 26.1 Million USD | 102.927% |
| Galecto, Inc. | -37.51 Million USD | 97.964% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 98.003% |
| Fortrea Holdings Inc. | 167.3 Million USD | 100.457% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 99.431% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 97.301% |
| XBiotech Inc. | -35.76 Million USD | 97.864% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 98.824% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 98.829% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 99.269% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 97.024% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 98.131% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 99.852% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 98.636% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -1263.044% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 99.343% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 96.554% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 99.675% |
| NexImmune, Inc. | -28.16 Million USD | 97.288% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 86.173% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 93.521% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.016% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 96.991% |
| Scopus BioPharma Inc. | -11.71 Million USD | 93.477% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 99.393% |
| Ainos, Inc. | -8.77 Million USD | 91.292% |
| Pluri Inc. | -20.22 Million USD | 96.222% |
| Prothena Corporation plc | -190.1 Million USD | 99.598% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 99.404% |
| Celularity Inc. | -183.94 Million USD | 99.585% |
| Rallybio Corporation | -72.37 Million USD | 98.944% |
| Cue Biopharma, Inc. | -46.05 Million USD | 98.341% |
| MeiraGTx Holdings plc | -57.05 Million USD | 98.661% |
| Omeros Corporation | -163.61 Million USD | 99.533% |
| Humacyte, Inc. | -96.45 Million USD | 99.208% |
| Immunocore Holdings plc | -59.64 Million USD | 98.719% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 96.056% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 96.864% |
| Blueprint Medicines Corporation | -474.61 Million USD | 99.839% |
| CalciMedica, Inc. | -34.18 Million USD | 97.765% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 98.957% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 99.546% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 99.697% |
| Pulmatrix, Inc. | -12.64 Million USD | 93.959% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 97.682% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 99.136% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 99.849% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 99.245% |
| Cytokinetics, Incorporated | -456.68 Million USD | 99.833% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 97.711% |
| Nutriband Inc. | -5.12 Million USD | 85.083% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 98.234% |
| Vor Biopharma Inc. | -114.37 Million USD | 99.332% |
| Roivant Sciences Ltd. | -996.51 Million USD | 99.923% |
| Evogene Ltd. | -23.2 Million USD | 96.707% |
| ProKidney Corp. | -147.66 Million USD | 99.483% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 98.816% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -398.861% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 99.865% |
| CorMedix Inc. | -48.88 Million USD | 98.437% |
| BioLineRx Ltd. | -57.06 Million USD | 98.661% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 99.316% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -278.218% |
| Atai Life Sciences N.V. | -36.31 Million USD | 97.896% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 99.039% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 99.06% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 99.723% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 97.515% |
| MediciNova, Inc. | -9.87 Million USD | 92.267% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 99.393% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 50.072% |
| GeoVax Labs, Inc. | -26.66 Million USD | 97.135% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 99.66% |
| Biomea Fusion, Inc. | -124.62 Million USD | 99.387% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 99.769% |
| Mereo BioPharma Group plc | -26.05 Million USD | 97.068% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 99.599% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 99.668% |
| Absci Corporation | -95.45 Million USD | 99.2% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 97.455% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 99.287% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 99.673% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 96.657% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 99.632% |
| Allakos Inc. | -189.91 Million USD | 99.598% |
| Imunon, Inc. | -19.87 Million USD | 96.157% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 99.296% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 100.705% |
| BioAtla, Inc. | -122.24 Million USD | 99.375% |
| NLS Pharmaceutics AG | -11.79 Million USD | 93.523% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 95.153% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 99.746% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 98.157% |
| XOMA Corporation | -39.36 Million USD | 98.059% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 99.23% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 99.351% |
| aTyr Pharma, Inc. | -52.17 Million USD | 98.536% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 99.088% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 99.486% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 99.674% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 94.404% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 90.5% |
| Akari Therapeutics, Plc | -16.8 Million USD | 95.453% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 504.863% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 100.169% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 88.041% |
| UroGen Pharma Ltd. | -63.83 Million USD | 98.803% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 98.875% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 89.481% |
| Orgenesis Inc. | -60.71 Million USD | 98.742% |
| Entera Bio Ltd. | -8.8 Million USD | 91.322% |
| GH Research PLC | -41.15 Million USD | 98.144% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 97.006% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 99.071% |
| Xencor, Inc. | -125.87 Million USD | 99.393% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 46.444% |
| Replimune Group, Inc. | -230.19 Million USD | 99.668% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 96.21% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 93.018% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 88.041% |
| Portage Biotech Inc. | -18.19 Million USD | 95.802% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 50.072% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 99.269% |
| OncoCyte Corporation | -23.12 Million USD | 96.696% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 93.239% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 93.331% |
| Purple Biotech Ltd. | -22.22 Million USD | 96.562% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 88.081% |
| scPharmaceuticals Inc. | -46.06 Million USD | 98.341% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 95.71% |
| HilleVax, Inc. | -132.46 Million USD | 99.423% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 92.815% |
| Tharimmune, Inc. | -9.3 Million USD | 91.787% |
| Genprex, Inc. | -31.06 Million USD | 97.54% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 99.593% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 97.563% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 606.282% |
| OKYO Pharma Limited | -15.74 Thousand USD | -4752.066% |
| Savara Inc. | -59.13 Million USD | 98.708% |
| Curis, Inc. | -45.13 Million USD | 98.307% |
| Daré Bioscience, Inc. | -30.7 Million USD | 97.512% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 94.971% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 89.337% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 97.142% |
| BeiGene, Ltd. | -1.12 Billion USD | 99.932% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 95.313% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 99.823% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 99.154% |
| Erasca, Inc. | -121.31 Million USD | 99.37% |
| bluebird bio, Inc. | -167.16 Million USD | 99.543% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 83.018% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 100.246% |
| DBV Technologies S.A. | -85.98 Million USD | 99.111% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 83.018% |
| Moderna, Inc. | -3.28 Billion USD | 99.977% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 98.207% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 86.473% |
| Molecular Templates, Inc. | 1.43 Million USD | 153.427% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 98.724% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 99.766% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 99.443% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 98.387% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 99.45% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 99.629% |
| MacroGenics, Inc. | 2.01 Million USD | 137.878% |
| RenovoRx, Inc. | -11.39 Million USD | 93.292% |
| Adicet Bio, Inc. | -136.53 Million USD | 99.44% |
| Prime Medicine, Inc. | -193.75 Million USD | 99.606% |
| Aditxt, Inc. | -25.45 Million USD | 96.999% |
| Adagene Inc. | -14.95 Million USD | 94.89% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 89.549% |
| Quantum-Si incorporated | -91.8 Million USD | 99.168% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 100.107% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 100.604% |
| SciSparc Ltd. | -5.28 Million USD | 85.536% |
| Vericel Corporation | 2.86 Million USD | 126.676% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -702.454% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 96.478% |
| Generation Bio Co. | -133.3 Million USD | 99.427% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 99.08% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 99.112% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 99.664% |
| Invivyd, Inc. | -196.61 Million USD | 99.611% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 99.796% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 91.763% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 102.814% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 92.572% |
| 2seventy bio, Inc. | -206.41 Million USD | 99.63% |
| ADMA Biologics, Inc. | 5.12 Million USD | 114.922% |
| Clene Inc. | -43.24 Million USD | 98.233% |
| Capricor Therapeutics, Inc. | -23 Million USD | 96.68% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 98.424% |
| GeoVax Labs, Inc. | -26.66 Million USD | 97.135% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 99.745% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 97.92% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 103.241% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 115.559% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 97.648% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 99.518% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 99.888% |
| Evaxion Biotech A/S | -21.4 Million USD | 96.43% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 98.85% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 99.649% |
| Trevena, Inc. | -35.28 Million USD | 97.835% |
| Surrozen, Inc. | -41.13 Million USD | 98.143% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 99.04% |
| Cingulate Inc. | -22.95 Million USD | 96.671% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 89.76% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 97.951% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 90.713% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 99.253% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 98.874% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 98.691% |
| Clearmind Medicine Inc. | -8.71 Million USD | 91.229% |
| Kronos Bio, Inc. | -121.83 Million USD | 99.373% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 98.972% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 68.707% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 99.242% |
| Statera Biopharma, Inc. | 38.93 Million USD | 101.962% |
| ImmunityBio, Inc. | -436.18 Million USD | 99.825% |
| Korro Bio, Inc. | -80.9 Million USD | 99.056% |
| Kineta, Inc. | -15.71 Million USD | 95.138% |
| BioVie Inc. | -31.95 Million USD | 97.609% |
| Codexis, Inc. | -49.28 Million USD | 98.45% |
| Celularity Inc. | -183.94 Million USD | 99.585% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 99.655% |
| Celcuity Inc. | -58.3 Million USD | 98.69% |
| Virax Biolabs Group Limited | -6.6 Million USD | 88.44% |
| Cibus, Inc. | -314.58 Million USD | 99.757% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 97.735% |
| IN8bio, Inc. | -28.5 Million USD | 97.32% |
| Kodiak Sciences Inc. | -259.02 Million USD | 99.705% |
| Annexon, Inc. | -141.57 Million USD | 99.46% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 99.321% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 98.81% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 97.267% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 99.668% |
| Eyenovia, Inc. | -24.1 Million USD | 96.831% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 101.706% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -135.802% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 98.965% |
| Arcellx, Inc. | -64.14 Million USD | 98.809% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 98.303% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 99.381% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 97.526% |
| Moolec Science SA | -52.07 Million USD | 98.533% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 98.52% |
| Geron Corporation | -174.78 Million USD | 99.563% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 98.11% |
| Royalty Pharma plc | 1.88 Billion USD | 100.04% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 99.361% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 91.806% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 96.316% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 99.54% |
| Humacyte, Inc. | -96.45 Million USD | 99.208% |
| Structure Therapeutics Inc. | -102.45 Million USD | 99.254% |
| 89bio, Inc. | -134.46 Million USD | 99.432% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 99.031% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 118.855% |
| Genelux Corporation | -24.16 Million USD | 96.838% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 97.74% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 99.533% |
| Notable Labs, Ltd. | -14.4 Million USD | 94.694% |
| Liquidia Corporation | -70.05 Million USD | 98.909% |
| Mustang Bio, Inc. | -48.06 Million USD | 98.41% |
| Immunovant, Inc. | -269.97 Million USD | 99.717% |
| Quantum-Si incorporated | -91.8 Million USD | 99.168% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 98.924% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 96.043% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 99.251% |
| Acasti Pharma Inc. | -11.3 Million USD | 93.24% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 96.567% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 95.017% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 99.637% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 82.109% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 95.189% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 97.345% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 97.937% |
| PepGen Inc. | -83.58 Million USD | 99.086% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 97.411% |
| United Therapeutics Corporation | 1.38 Billion USD | 100.055% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 96.663% |
| Solid Biosciences Inc. | -93.43 Million USD | 99.182% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 83.989% |
| Immuneering Corporation | -58.06 Million USD | 98.684% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 23922.887% |
| Silo Pharma, Inc. | -3.62 Million USD | 78.931% |
| Belite Bio, Inc | -31.52 Million USD | 97.577% |
| XOMA Corporation | -39.36 Million USD | 98.059% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 98.867% |
| Bionomics Limited | -9.83 Million USD | 92.233% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 99.09% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 97.792% |
| uniQure N.V. | -253.1 Million USD | 99.698% |
| Cassava Sciences, Inc. | -95.68 Million USD | 99.202% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 89.549% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 99.41% |
| Forte Biosciences, Inc. | -32.47 Million USD | 97.648% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 90.51% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 97.293% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -135.802% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 93.142% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 95.195% |
| Altimmune, Inc. | -87.93 Million USD | 99.131% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 99.17% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 97.792% |
| Compugen Ltd. | -12.51 Million USD | 93.896% |
| Peak Bio, Inc. | -1356.23 USD | -56232.628% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 98.428% |
| Benitec Biopharma Inc. | -22.49 Million USD | 96.603% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 99.685% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 97.323% |
| Zura Bio Limited | -60.56 Million USD | 98.739% |
| PolyPid Ltd. | -20.26 Million USD | 96.23% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 95.107% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 97.323% |
| Instil Bio, Inc. | -146.12 Million USD | 99.477% |
| argenx SE | -216.02 Million USD | 99.646% |
| Immunome, Inc. | -28.27 Million USD | 97.298% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 98.424% |
| Verona Pharma plc | -52.46 Million USD | 98.544% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 99.194% |
| Shattuck Labs, Inc. | -87.61 Million USD | 99.128% |
| CervoMed Inc. | -2.17 Million USD | 64.823% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 99.375% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 93.981% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 98.414% |
| Moolec Science SA | -52.07 Million USD | 98.533% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 95.543% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 99.414% |
| AnaptysBio, Inc. | -143.16 Million USD | 99.466% |
| Design Therapeutics, Inc. | -66.32 Million USD | 98.848% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 99.057% |
| NeurAxis, Inc. | -6.66 Million USD | 88.536% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 97.976% |
| Lumos Pharma, Inc. | -36.57 Million USD | 97.911% |
| Achilles Therapeutics plc | -70.44 Million USD | 98.915% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 99.194% |
| 180 Life Sciences Corp. | -22.13 Million USD | 96.548% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 113.106% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 68.707% |
| Nutriband Inc. | -5.12 Million USD | 85.083% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 99.304% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 98.622% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 98.489% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 98.83% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 98.588% |
| Palisade Bio, Inc. | -12.28 Million USD | 93.779% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 98.316% |
| Beam Therapeutics Inc. | -156.47 Million USD | 99.512% |
| Neurogene Inc. | -52.28 Million USD | 98.539% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 99.44% |
| AEON Biopharma, Inc. | -48.36 Million USD | 98.42% |
| Sesen Bio, Inc. | -50.84 Million USD | 98.497% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 99.068% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 93.814% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 99.821% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 99.274% |
| Athira Pharma, Inc. | -116.7 Million USD | 99.345% |
| Vaccinex, Inc. | -19.74 Million USD | 96.131% |
| HCW Biologics Inc. | -23.57 Million USD | 96.759% |
| XOMA Corporation | -39.36 Million USD | 98.059% |
| Nektar Therapeutics | -243.1 Million USD | 99.686% |
| Arvinas, Inc. | -394.8 Million USD | 99.806% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 504.863% |
| Merus N.V. | -149.2 Million USD | 99.488% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 99.183% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 97.556% |
| Rezolute, Inc. | -68.42 Million USD | 98.883% |
| Clene Inc. | -43.24 Million USD | 98.233% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 95.046% |
| BeyondSpring Inc. | -21.54 Million USD | 96.453% |
| Synlogic, Inc. | -55.16 Million USD | 98.615% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 93.677% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 92.821% |
| Peak Bio, Inc. | -1356.23 USD | -56232.628% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 97.647% |
| Krystal Biotech, Inc. | 17.9 Million USD | 104.267% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 99.355% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 99.776% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 83.414% |
| MannKind Corporation | 15.12 Million USD | 105.05% |
| Ikena Oncology, Inc. | -74.39 Million USD | 98.973% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 93.933% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 103.759% |
| Gossamer Bio, Inc. | -172.15 Million USD | 99.556% |
| CohBar, Inc. | -12.06 Million USD | 93.668% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 97.005% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 97.455% |
| Legend Biotech Corporation | -477.87 Million USD | 99.84% |
| Mural Oncology plc | -192.72 Million USD | 99.604% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.33% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 95.268% |
| Disc Medicine, Inc. | -91.02 Million USD | 99.161% |
| Champions Oncology, Inc. | -5.05 Million USD | 84.883% |
| REGENXBIO Inc. | -239.46 Million USD | 99.681% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 92.872% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 98.63% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 98.029% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 99.323% |
| Vaxart, Inc. | -74.72 Million USD | 98.978% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 97.83% |
| Cellectis S.A. | -98.09 Million USD | 99.221% |
| Longeveron Inc. | -20.06 Million USD | 96.191% |
| Repare Therapeutics Inc. | -114.27 Million USD | 99.331% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 99.826% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 98.979% |
| Revolution Medicines, Inc. | -430.58 Million USD | 99.823% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 87.852% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 97.519% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 98.976% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 115.582% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 93.032% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.017% |
| Denali Therapeutics Inc. | -179.97 Million USD | 99.575% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -702.454% |
| Veru Inc. | -89.97 Million USD | 99.151% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 97.158% |
| Cingulate Inc. | -22.95 Million USD | 96.671% |
| Passage Bio, Inc. | -98.34 Million USD | 99.223% |
| Context Therapeutics Inc. | -25.06 Million USD | 96.951% |
| Exicure, Inc. | -15.53 Million USD | 95.083% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 99.629% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 97.934% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 87.187% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 99.546% |
| Nuvalent, Inc. | -149.49 Million USD | 99.489% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 90.605% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 99.111% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 97.468% |
| OmniAb, Inc. | -49.73 Million USD | 98.464% |
| Anew Medical, Inc. | -1.3 Million USD | 41.269% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 93.821% |
| Lipocine Inc. | -16.32 Million USD | 95.319% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 98.854% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 98.972% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 97.996% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 98.042% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 96.556% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 99.86% |
| Ocugen, Inc. | -64.82 Million USD | 98.821% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 99.175% |
| Q32 Bio Inc. | -86.5 Million USD | 99.117% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 95.487% |
| Alumis Inc. Common Stock | -156.89 Million USD | 99.513% |
| Equillium, Inc. | -12.13 Million USD | 93.706% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 98.693% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 90.333% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 95.949% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 98.364% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.282% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 95.729% |
| Dominari Holdings Inc. | -22.44 Million USD | 96.595% |
| Edesa Biotech, Inc. | -8.19 Million USD | 90.672% |
| vTv Therapeutics Inc. | -25.41 Million USD | 96.994% |
| Bio-Techne Corporation | 326.66 Million USD | 100.234% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 99.801% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 100.353% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 99.417% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 97.959% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 99.494% |
| Nkarta, Inc. | -120.48 Million USD | 99.366% |
| BioCardia, Inc. | -11.56 Million USD | 93.391% |
| Iterum Therapeutics plc | -34.58 Million USD | 97.791% |